InsiderTrades.com logo
Patrick Burnett net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Patrick Burnett Biography and Net Worth

Insider of Arcutis Biotherapeutics
Patrick Burnett has served as Arcutis’ chief medical officer since August 2020. Prior to that, Dr Burnett was the chief medical officer at Verrica Pharmaceuticals since April 2018. Prior to that, Dr Burnett was at Sun Pharmaceuticals where he was associate vice president of clinical development from September 2015 to March 2018, with oversight of the dermatology and rheumatology pipeline. Prior to Sun, Dr Burnett was at Novartis from 2010 to August 2015, most recently as global program medical director. He is a board-certified dermatologist and was a member of the medical faculty at Vanderbilt University Medical Center as an assistant professor of dermatology from 2004 to 2010. Dr Burnett holds an MD and PhD in neuroscience from Johns Hopkins School of Medicine and a BS in biology and biochemistry from the University of Iowa.

What is Patrick Burnett's net worth?

The estimated net worth of Patrick Burnett is at least $2.02 million as of March 14th, 2025. Dr. Burnett owns 121,936 shares of Arcutis Biotherapeutics stock worth more than $2,015,480 as of March 26th. This net worth estimate does not reflect any other assets that Dr. Burnett may own. Additionally, Dr. Burnett receives an annual salary of $722,940.00 as Insider at Arcutis Biotherapeutics. Learn More about Patrick Burnett's net worth.

How old is Patrick Burnett?

Dr. Burnett is currently 52 years old. There are 6 older executives and no younger executives at Arcutis Biotherapeutics. The oldest executive at Arcutis Biotherapeutics is Dr. Bhaskar Chaudhuri Ph.D., Co-Founder & Independent Director, who is 69 years old. Learn More on Patrick Burnett's age.

What is Patrick Burnett's salary?

As the Insider of Arcutis Biotherapeutics, Inc., Dr. Burnett earns $722,940.00 per year. There are 2 executives that earn more than Dr. Burnett. The highest earning executive at Arcutis Biotherapeutics is Mr. Todd Franklin Watanabe M.A., President, CEO & Director, who commands a salary of $1,010,000.00 per year. Learn More on Patrick Burnett's salary.

How do I contact Patrick Burnett?

The corporate mailing address for Dr. Burnett and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at ir@arcutis.com. Learn More on Patrick Burnett's contact information.

Has Patrick Burnett been buying or selling shares of Arcutis Biotherapeutics?

Within the last three months, Patrick Burnett has sold $220,851.25 in Arcutis Biotherapeutics stock. Most recently, Patrick Burnett sold 12,242 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $15.04, for a transaction totalling $184,119.68. Following the completion of the sale, the insider now directly owns 121,936 shares of the company's stock, valued at $1,833,917.44. Learn More on Patrick Burnett's trading history.

Who are Arcutis Biotherapeutics' active insiders?

Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.

Are insiders buying or selling shares of Arcutis Biotherapeutics?

During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 1,093 shares worth more than $7,771.23. During the last year, insiders at the sold shares 27 times. They sold a total of 217,604 shares worth more than $2,419,803.42. The most recent insider tranaction occured on March, 17th when insider Todd Franklin Watanabe sold 1,200 shares worth more than $21,132.00. Insiders at Arcutis Biotherapeutics own 9.5% of the company. Learn More about insider trades at Arcutis Biotherapeutics.

Information on this page was last updated on 3/17/2025.

Patrick Burnett Insider Trading History at Arcutis Biotherapeutics

See Full Table

Patrick Burnett Buying and Selling Activity at Arcutis Biotherapeutics

This chart shows Patrick Burnett's buying and selling at Arcutis Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$221ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics logo
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More

Today's Range

Now: $16.47
Low: $16.38
High: $17.55

50 Day Range

MA: $13.82
Low: $11.40
High: $17.29

2 Week Range

Now: $16.47
Low: $6.99
High: $17.75

Volume

1,556,072 shs

Average Volume

2,384,722 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48